I
ntroducing STAT’s Biotech Q4 Scorecard: Ten companies with important clinical trial and FDA milestones scheduled to read out over the next three months. We’ll use emojis to track the winners and losers as the outcomes are announced. Scroll down for a short explanation of each company and its pivotal readout.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Hello Adam,
Are you considering the KITE/GILEAD axi-cel approval on/about November 29 FDA PDUFA date a forgone conclusion? It won’t exactly “break” Gilead with a CRL (Complete Response Letter) but if that happens, don’t you think it would result in a huge drop in the stock price?